Penicillin V and erythromycin have no benefit for most adults with acute laryngitis

NewsGuard 100/100 Score

Two common antibiotics, Penicillin V and erythromycin, appear to have no benefit for most adults with acute laryngitis, says a research team led by Dr. Ludovic Reveiz of Bogota, Colombia.

Arguments against prescribing antibiotics include cost, adverse side effects and possible contribution to antibiotic resistance. The authors reviewed existing scientific literature and cautioned that definitive recommendations cannot be made because solid results are available from only two randomized controlled trials, studies with the highest standard of evidence.

Acute infectious laryngitis is usually caused by viral infection; however, bacterial pathogens can often be isolated in patients as well. Upper respiratory tract infections represent a frequent reason for prescribing antibiotics in ambulatory practice and primary care, the authors say.

In each study, approximately 100 adult laryngitis patients received either antibiotic or a placebo. Repeated voice recordings provided an objective measure of symptoms, and no significant differences were found between the groups.

“These findings support the conclusion that the disorder is generally self-limiting, and maybe the majority of patients in the studies were suffering from viral [infections].”

Additional research should examine the role of bacterial infection in acute laryngitis, say the authors. Any subsequent increases in antibiotic resistance should also be described.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer